Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company La Jolla Pharmaceutical Co.
DescriptionThe kinase inhibitor targeting bone morphogenetic protein receptor type I (BMPRI)
Molecular Target Bone morphogenetic protein receptor type I (BMPRI)
Mechanism of ActionKinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Musculoskeletal (unspecified)
Indication DetailsTreat fibrodysplasia ossificans progressiva (FOP)
Regulatory Designation U.S. - Orphan Drug (Treat fibrodysplasia ossificans progressiva (FOP))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today